Management of comorbid diabetes mellitus and worsening heart failure

JAMA

Volumn 311, Issue 23, 2014, Pages 2379-2380

  Khan, Sadiya S ^a   Butler, Javed ^b   Gheorghiade, Mihai ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; SAXAGLIPTIN;

CARDIOMYOPATHY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HEALTH CARE MANAGEMENT; HEART FAILURE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; INCIDENCE; INSULIN RESISTANCE; KIDNEY FAILURE; KIDNEY FUNCTION; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; SHORT SURVEY; SURVIVAL RATE; UNITED STATES;

COMORBIDITY; DIABETES MELLITUS; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HEART FAILURE; HUMANS; PREVALENCE; RISK;

EID: 84902589950     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.4115     Document Type: Short Survey

References (10)

1. Go AS, Mozaffarian D, Roger VL, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28-e292.
2. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC Jr. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care. 2004;27(3):699-703. (Pubitemid 38280536)
3. Greenberg BH, Abraham WT, Albert NM, et al Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J. 2007;154(2):277.e1-277.e8.
4. Sarma S, Mentz RJ, Kwasny MJ, et al; EVEREST investigators. Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. Eur J Heart Fail. 2013;15(2):194-202.
5. Maggioni AP, Greene SJ, Fonarow GC, et al; ASTRONAUT Investigators and Coordinators. Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. Eur Heart J. 2013;34(40):3117-3127.
6. Shah SJ, Heitner JF, Sweitzer NK, et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail. 2013;6(2):184-192.
7. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412. (Pubitemid 30609442)
8. van Herpen NA, Schrauwen-Hinderling VB. Lipid accumulation in non-adipose tissue and lipotoxicity. Physiol Behav. 2008;94(2):231-241. (Pubitemid 351615422)
9. Das SR, Drazner MH, Yancy CW, Stevenson LW, Gersh BJ, Dries DL. Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial. Am Heart J. 2004;148(5):883-888.
10. Home PD, Pocock SJ, Beck-Nielsen H, et al; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125-2135.